Pharmaceutical Technology

FEBRUARY 3, 2023

The failure of several late-stage trials highlights the challenging nature of HIV vaccine development. Since HIV integrates with the DNA, eliminating the virus from the body is very difficult, explains David Montefiori, PhD, director of the Laboratory for AIDS Vaccine Research and Development at Duke University in Durham, North Carolina.

Vaccine 293

Vaccine Vaccination Antibody Trials 293

The Pharma Data

SEPTEMBER 10, 2020

Pfizer-BioNTech announced Wednesday that preliminary preclinical data from mouse and macaque monkey models showed a strong immune response from its mRNA COVID-19 vaccine. . Photo by Md. Tareq Aziz Touhid. The study and the data are currently subject to peer review.

Immune Response 52

Immune Response Vaccine Vaccination RNA 52

The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.

Immune Response 52

Immune Response Vaccine Vaccination Antibody 52

The Pharma Data

MAY 17, 2021

The interim results from the phase 2 trial on the vaccine, published today, on the contrary, showed a “ strong neutralizing antibody response” ? The companies also noted a high immune response after a single dose of the shot in patients with prior infection, indicating, they said, strong booster potential for the jab. “

Immune Response 52

Immune Response Vaccine Vaccination Antibody 52

pharmaphorum

OCTOBER 12, 2022

Now, he leads Whitelab Genomics as its artificial intelligence (AI) platform powers the development of genomic therapies – an emerging field in which genetic sequences are injected into cells to target and repair damaged genes. The payload, Del Bourgo tell us, is the therapeutic DNA or RNA sequence that will cure or fix damaged cells.

Genome 105

Genome Genomics Medicine Development 105

pharmaphorum

SEPTEMBER 23, 2021

AstraZeneca has joined the ranks of big pharma companies bolting on RNA-based technology platforms in the wake of the stellar success of mRNA vaccines for COVID-19. Along with the equity investment and milestones, AZ will also provide R&D funding to projects that enter into development.

RNA 52

RNA Immune Response Vaccine Vaccination 52

Pharmaceutical Technology

NOVEMBER 22, 2022

Vaccines are our number one weapon in the fight against infectious diseases, but their development has historically involved a long and complex process taking up to a decade. Before COVID-19, Merck held the record for the fastest modern vaccine ever developed. million in funding to support this work.

Manufacturing 130

Manufacturing Vaccine Vaccination RNA 130

pharmaphorum

JULY 6, 2021

PCR tests screen for the presence of viral RNA from a swab, detecting whether an individual is currently infected. Because antibody tests detect neutralising antibodies rather than monitoring for an active infection, a positive result can prove that the immune system has developed the capacity to defeat a future infection.

Antibody 111

Antibody Immune Response Protein Vaccine 111

pharmaphorum

AUGUST 31, 2021

Just a few months after breaking cover with its new take on RNA therapeutics, Laronde has raised an impressive $440 million in second-round financing backed by Flagship Pioneering – which was behind the founding of mRNA specialist Moderna. The post ‘Endless RNA’ startup Laronde raises $440m to fuel pipeline appeared first on.

RNA 52

RNA Protein Immune Response Medicine 52

pharmaphorum

JANUARY 5, 2022

A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinical trial.

Protein 126

Protein Vaccine Vaccination Immune Response 126

Roots Analysis

OCTOBER 30, 2023

In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.

RNA 40

RNA Vaccine Vaccination Development 40

Delveinsight

SEPTEMBER 23, 2021

858 Therapeutics closes USD 60 Million series A round to drug RNA modulation. Now, they are ready for their next venture, which is launching RNA biotech 858 Therapeutics with a USD 60 million Series A fundraising. 858’s drug candidates include proteins, which regulate RNA and immune response. Stafford and co.

RNA 61

RNA Gene Therapy Gene Protein 61

Pharmaceutical Technology

FEBRUARY 15, 2023

The non-structural proteins NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 are involved in viral RNA replication and dampening of the host innate immune response. The company is involved in developing several vaccines for yellow fever, Japanese Encephalitis, Flavivirus Tick-borne encephalitis, and dengue fever.

Vaccine 130

Vaccine Vaccination Protein Immune Response 130

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility. Karim Beguir – InstaDeep.

Vaccination 116

Vaccination Vaccine Clinical Trials Clinical Trials 116

Delveinsight

AUGUST 26, 2021

Seattle biotech firm Shape Therapeutics has signed a deal potentially exceeding USD 3 billion with pharma giant Roche to bolster the development of gene therapies for Alzheimer’s and Parkinson’s disease. Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks.

Vaccine 98

Vaccine Vaccination Gene Therapy RNA 98

XTalks

NOVEMBER 30, 2023

Global entities such as the WHO, the Global Fund and the Joint United Nations Programme on HIV/AIDS (UNAIDS) have developed comprehensive strategies aligned with Sustainable Development Goal (SDG) target 3.3, These findings signify a significant step forward in the development of AGT103-T as a potential gene therapy for HIV.

FDA Approval 111

FDA Approval Gene Therapy Gene Clinical Trials 111

Worldwide Clinical Trials

JUNE 15, 2022

At the end of May, we hosted a webinar titled “ Changing Times, Changing Therapies: Keeping Up with Advancements in Cell and Gene Therapies ” to provide a quick update on the latest advancements and ongoing in development of these advanced therapeutics. Clinical holds are becoming more common, especially in gene therapy programs.

Gene Therapy 130

Gene Therapy Gene Clinical Trials Clinical Trials 130

pharmaphorum

OCTOBER 2, 2020

Roche’s Genentech unit has paid $200 million to develop an individualised cancer vaccine with Norwegian biotech Vaccibody, which focuses on targets known as neoantigens that spring up as tumours grow and mutate. Frame Therapeutics has also begun work on neoantigen-based cancer vaccines based on RNA technology.

Vaccine 59

Vaccine Vaccination Immune Response Drugs 59

pharmaphorum

OCTOBER 6, 2020

The European Medicines Agency has begun a second “rolling review” of a potential coronavirus vaccine jointly developed by BioNTech and Pfizer, setting up a race with a rival from AstraZeneca and Oxford University. According to latest figures from the World Health Organization, there are 42 potential COVID-19 vaccines in clinical development.

Vaccine 59

Vaccine Vaccination RNA Immune Response 59

VirTrial

OCTOBER 25, 2023

While vaccine development has come a long way, there is much to accomplish in the future. Let’s take a brief look at the history of vaccines, how the COVID-19 pandemic changed the landscape, and where the future of vaccine development is headed. Today, smallpox is the only human disease to have been eradicated.

Vaccine 52

Vaccine Vaccination Development Clinical Trials 52

The Pharma Data

MARCH 8, 2022

While the development of vaccines was accomplished in a remarkably short timeframe, the identification of direct antiviral treatments has progressed comparatively slowly. Proteins of SARS-CoV-2 can alter viral ribonucleic acids in a way, that they become indistinguishable from endogenous RNA.

Immune Response 52

Immune Response RNA Protein Genetics 52

The Pharma Data

DECEMBER 3, 2020

Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. Based on the positive Phase 1 results reported and the unprecedented need for COVID-19 vaccines, Clover and its partners are confident to enter late-stage clinical development for both adjuvanted vaccines.

Vaccine 52

Vaccine Vaccination Immune Response Protein 52

pharmaphorum

FEBRUARY 9, 2021

InteRNA is focusing on the development of gene-silencing drugs based on microRNA, naturally occurring, non-coding strands of RNA that are thought to regulate gene expression in cells.

Trials 59

Trials Gene Silencing RNA Gene Expression 59

Find Me Cure

OCTOBER 13, 2019

If you follow our blog you know that we at FindMeCure take updating our readership on treatments in development very seriously. The case that illustrates the new approach being developed is that of a metastatic breast cancer patient who came to the trial after trying everything else.

Development 52

Development DNA Clinical Trials Clinical Trials 52

The Pharma Data

JUNE 26, 2021

BNT111 is the lead product candidate from BioNTech’s FixVac platform that targets a fixed combination of mRNA-encoded, tumor-associated antigens with the objective of triggering a strong and precise immune response against cancer and is fully owned by BioNTech. About FixVac.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Immune Response 52

The Pharma Data

MAY 17, 2021

Sanofi and GlaxoSmithKline (GSK) have reemerged as COVID-19 vaccine contenders after their reformulated candidate delivered a strong immune response across all age groups in a phase 2 study. 14, 2020 ). The mRNA candidate is currently being assessed in a phase 1/2 study.

Vaccine 40

Vaccine Vaccination Immune Response RNA 40

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. These findings give confidence that Clover’s COVID-19 vaccine candidates are suitable for further clinical development.”

Clinical Trials 52

Clinical Trials Clinical Trials Vaccine Vaccination 52

XTalks

JUNE 5, 2023

Today’s approval is a monumental step forward in delivering on Pfizer’s commitment to help alleviate the significant burden of RSV in higher-risk populations, which includes older adults,” said Annaliesa Anderson, PhD, senior VP and chief scientific officer, Vaccine Research and Development at Pfizer, in the company’s news release.

Vaccine 98

Vaccine Vaccination FDA Approval Protein 98

The Pharma Data

JULY 18, 2021

Clinical Data Supporting Approval Demonstrated Non-Inferior Immune Responses for the Serotypes Shared with PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F). VAXNEUVANCE Elicited Superior Immune Responses for Serotypes 3, 22F and 33F Compared to PCV13, Which Are Major Causes of Disease.

Immune Response 52

Immune Response Vaccine Vaccination FDA Approval 52

pharmaphorum

NOVEMBER 2, 2022

billion on offer in milestones if the programmes meet development and commercial objectives. According to a statement from the two companies, Arcturus will contribute its STARR self-amplifying mRNA vaccine and LUNAR lipid nanoparticle delivery platform, which has already been deployed in the development of COVID-19 vaccine ARCT-154.

Vaccine 52

Vaccine Vaccination Immune Response Gene Therapy 52

pharmaphorum

JANUARY 17, 2023

Once its potential as a means of stimulating an immune response had been established, attention quickly turned to where else the technology could provide a therapeutic solution. The intracellular barriers include endosomal escape, RNA sensors, and endonucleases.

Vaccination 97

Vaccination Vaccine In-Vivo In-Vitro 97

The Pharma Data

JUNE 26, 2021

Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza. JUNE 22 , 2021.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccine Vaccination 52

XTalks

MARCH 10, 2021

Along with COVID-19 vaccine authorizations, the US Food and Drug Administration (FDA) remains committed to increasing access to COVID-19 tests and supporting their development, having authorized three new tests recently for emergency use. The products encompass molecular, antigen and T cell-based testing approaches.

Protein 98

Protein RNA Antibody Production 98

pharmaphorum

NOVEMBER 4, 2022

The influenza virus is subject to constant mutations to evade host immune response, and this causes the seasonal variation in circulating strains. This will help us to further develop our infectious disease pipeline to deliver on patient centric vaccination approaches.”.

Vaccine 52

Vaccine Vaccination Immune Response RNA 52

The Pharma Data

SEPTEMBER 30, 2021

“We used NanoSTING because the adjuvant for intranasal vaccination and single-cell RNA-sequencing to verify the nasal-associated lymphatic tissue as an inductive site upon vaccination. A fundamental limitation of intramuscular vaccines is that they’re not designed to elicit mucosal immunity. Breathe in, exhale.

Vaccine 52

Vaccine Vaccination Immune Response Licensing 52

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The joint development team is working on improving the temperature stability of the mRNA vaccine candidate and targeting a -20°C storage temperature for late-stage clinical trials and at launch.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccine Vaccination 52

The Pharma Data

JUNE 25, 2021

“In addition, the variant-rich environment underlines the importance of developing next-generation vaccines as new virus variants continue to emerge.” CureVac remains committed to COVID-19 vaccine development. Beyond CVnCoV, the company develops in partnership with GSK second-generation COVID-19 vaccine candidates.

Vaccine 52

Vaccine Vaccination Trials Immune Response 52